Health technology assessment: Reflections from the antipodes

Value in Health

Volumn 12, Issue SUPPL. 2, 2009, Pages

  Bulfone, Liliana ^a   Younie, Sandra ^a   Carter, Rob ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Australia; Health technology assessment; HTA; PBAC

Indexed keywords

AUSTRALIA; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL SERVICE; MEDICAL TECHNOLOGY; MEDICARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW;

EID: 66549120930     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00556.x     Document Type: Article

References (13)

1. Australian Institute of Health and Welfare 2008. Health expenditure Australia 2006-2007. Health and Welfare Expenditure Series no. 35. Cat. no. HWE 42. Canberra : AIHW, 2008. Data source: Table a.3 (p. 120). Available from: http://www.aihw.gov.au/publications/hwe/hea06-07/hea06-07.pdf [Accessed January 2, 2008 DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff 2001 20 : 104 14.
2. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/ Content/evaluation-cycle-1 [Accessed August 6, 2007 A, Bulfone L. Getting value for money: the Australian experience. In : Jost TS, ed., Health Care Coverage Determinations: An International Comparative Study. Maidenhead : Open University Press, 2005.
3. MSAC Application Process: Guidelines. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/guidelines-1 [Accessed August 28, 2007 C, Drazen JM, Frizelle FA, Haug C, et al. Clinical trial registration [editorial]. A statement from the International Committee of Medical Journal Editors. Med J Aust 2004 181 : 293 4.
4. DeAngelis C, Drazen JM, Frizelle FA, Haug C, et al. Is this clinical trial fully registered? [editorial]. A statement from the International Committee of Medical Journal Editors. Med J Aust 2005 182 : 609 10.
5. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008 28 : 713 22.
6. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18 : 341 64.
7. Drummond M, Pang F. Transferability of economic evaluation results. In : Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Oxford : Oxford University Press, 2001.
8. Working Together to Improve the Pharmaceutical Benefits Scheme: Review of Post PBAC Processes Report. 2004 Department of Health and Ageing. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/ B3CE8CB96EB0E3A6CA2573FC001C4319/$File/pbacprocess.pdf [Accessed September 2, 2007 2005, Impacts of Advances in Medical Technology in Australia, Research Report, Melbourne.
9. Official Committee Hansard. Senate: Community Affairs Legislation Committee. Consideration of Additional Estimates. Monday, 19 February 2001. Canberra. Available from: http://www.aph.gov.au/HANSARD/senate/commttee/s4564. pdf [Accessed September 2, 2007 Australian Broadcasting Corporation. Four Corners. Reporter Liz Jackson. Available from: http://www.abc.net.au/4corners/ stories/s248583.htm [Accessed September 2, 2007 DA, Birkett DJ. Changes to the Pharmaceutical Benefits Advisory Committee: Any proposed change in the Committee's role should be communicated widely. MJA 2001 174 : 209 10. Available from: http://www.mja.com.au/public/issues/174-05-050301/henry/henry.html [Accessed September 2, 2007 L, Walker A, Waters AM, Harding A, Thurecht L. Funding of High Cost Biotechnology and Other Innovative Targeted Therapies under the Pharmaceutical Benefits Scheme. National Centre for Social and Economic Modelling. NATSEM. University of Canberra. Position Paper. 27 February 2002. Available from: http://www.pc.gov.au/projects/study/medicaltechnology/docs/ submissions [Accessed September 2, 2007 KI, Lu CY, O'Day R. Can we deny patients expensive drugs Aust Prescr 2006 29 : 146 8. Available from: http://www.australianprescriber.com/magazine/29/6/146/8 [Accessed September 3, 2007 R, Francis H, Read K. The Australian government's review of positron emission tomography: evidence-based policy making in action. Med J Aust 2004 180 : 627 32 and responses: Davies P. The Australian government's review of positron emission tomography: an open door. Med J Aust 2004;180:633; Ware R, Francis J, Read K. Med J Aust 181:516-7.
10. Productivity Commission 2003. Evaluation of the pharmaceutical industry investment program, Research Report, AusInfo, Canberra. Page 3.10. Available from: http://www.pc.gov.au/projects/study/piip/docs/finalreport.
11. Reference Pricing Subcommittee Report (Fifth Draft). West Virginia Pharmaceutical Cost Management Council (Rx Council). Available from: http://www.state.wv.us/got/pharmacycouncil/ReferencePricingReport-Draft5.pdf [Accessed August 6, 2007 2005. Impacts of Advances in Medical Technology in Australia, Research Report, Melbourne. Available from: http://www.pc.gov.au/ projects/study/medicaltechnology/docs/finalreport [Accessed September 3, 2007].
12. Health and Ageing Factbook 2006. Department of Health and Ageing. Canberra. Chapter 2. Available at: http://www.health.gov.au/internet/main/ publishing.nsf/Content/Factbook2006-1 [Accessed September 4, 2007 DM. Health technology assessment in Canada: diversity and evolution. Med J Aust 2007 187 : 286 8.
13. Central Intelligence Agency. The World Factbook. Australia. Available from: [Accessed September 3, 2007 TJ. Health technology assessment in Australia: challenges ahead. Med J Aust 2007 187 : 262 4.